TargetMol

Rocepafant

Product Code:
 
TAR-T28607
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28607-1mg1mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28607-5mg5mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28607-10mg10mg£279.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28607-25mg25mg£477.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28607-50mg50mg£625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28607-100mg100mg£859.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rocepafant is a platelet activating factor (PAF) antagonist. BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. BN 50730 also inhibits tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cells.
CAS:
132579-32-9
Formula:
C26H23ClN6OS2
Molecular Weight:
535.08
Purity:
0.98
SMILES:
COc1ccc(NC(=S)N2CCc3c(C2)sc-2c3C(=NCc3nnc(C)n-23)c2ccccc2Cl)cc1
Target:
Platelet aggregation

References

1. Liu XH, Eun BL, Barks JD. Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11. PubMed PMID: 11385142. 2. Singh N, Sharma A, Singh M. Effects of BN-50730 (PAF receptor antagonist) and physostigmine (AChE inhibitor) on learning and memory in mice. Methods Find Exp Clin Pharmacol. 1997 Nov;19(9):585-8. PubMed PMID: 9500121. 3. Silva CL, Cruz HN, Violante FA, Cordeiro RS, Martins MA, No?l F. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes. Biochem Pharmacol. 1996 Jan 26;51(2):193-6. PubMed PMID: 8615889. 4. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol. 1995 Sep;22(9):1651-4. PubMed PMID: 8523338.